LONDON, April 8, 2014 /PRNewswire/ --
On Monday, April 07, 2014, the NASDAQ Composite ended at 4,079.75, down 1.16%, the Dow Jones Industrial Average finished the session 1.02% lower at 16,245.87, and the S&P 500 closed at 1,845.04, down 1.08%. The losses were broad based as nine out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index finished the day 1.06% lower at 664.68, while the same has gained 3.19% in the previous three months. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corp. (NASDAQ: CELG), PDL BioPharma Inc. (NASDAQ: PDLI) and Hemispherx Biopharma Inc. (NYSE MKT: HEB). Free technical research on ARNA, CELG, PDLI and HEB can be downloaded upon signing up at:
On Monday, shares in Arena Pharmaceuticals Inc. gained 2.57% to close the day at $6.38. The stock recorded a trading volume of 5.82 million shares, as compared with its three months average volume of 6.14 million shares. The stock oscillated between $6.08 and $6.42 during the trading session. Arena Pharmaceuticals Inc.'s shares have fallen by 4.35% in the previous three trading sessions and 10.39% in the last one month, while the same has gained 9.06% on YTD basis. The stock is trading below its 50-day moving average. Arena Pharmaceuticals Inc.'s 50-day moving average of $6.61 is above its 200-day moving average of $6.25. Moreover, the stock has a Relative Strength Index (RSI) of 43.96. Sign up today to read free research on ARNA at:
Celgene Corp.'s stock finished the session 1.30% higher at $139.16. A total of 6.77 million shares were traded, which is above their three months average volume of 3.75 million shares. The stock fluctuated between $135.50 and $140.68 during the session. The company's shares traded at a PE ratio of 29.73. Celgene Corp.'s stock has declined 5.60% in the previous three trading sessions, 11.11% in the last one month and 17.64% on YTD basis. The stock is trading below its 50-day and 200-day moving averages of $154.44 and $150.71, respectively. Additionally, the stock has an RSI of 33.97. Sign up today to read free research on CELG at:
On Monday, PDL BioPharma Inc.'s stock recorded a trading volume of 4.08 million shares, as compared with its three months average volume of 3.19 million shares. The stock ended the day at $8.20, up 1.74%, after vacillating between $7.98 and $8.24. Shares of the company traded at a PE ratio of 4.74. PDL BioPharma Inc.'s shares have lost 0.97% in the previous three trading sessions, 0.85% in the last one month and 2.84% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $8.47 and $8.31, respectively. Furthermore, shares of the company have an RSI of 42.16. Sign up today to read free research on PDLI at:
Shares in Hemispherx Biopharma Inc. reported a trading volume of 0.71 million shares, as compared with its three months average volume of 3.36 million shares. The stock ended the day 6.13% lower at $0.38, and at an intraday range of $0.37 and $0.39. Hemispherx Biopharma Inc.'s shares have fallen by 7.05% in the previous three trading sessions and 5.22% in the last month, while the stock has gained 41.70% on YTD basis. The stock is trading below its 50-day moving average. Hemispherx Biopharma Inc.'s 50-day moving average of $0.41 is above its 200-day moving average of $0.29. Further, the stock has an RSI of 48.86. Sign up today to read free research on HEB at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.